transplant centres representing 17 health regions gave data on more than 1200 transplants from living donors. Transplants from living donors accounted for 0-25% of the total experience of health regions. Two centres had abandoned living donor transplantation. Sixty per cent of transplant surgeons favoured expansion of the living donor programme to meet a shortage of kidneys from cadavers, and the remainder thought that existing programmes were optimal.
Living donor transplantation promises to be an important factor in the future planning of health care resources.
Introduction
When reviewing kidney transplantation in Leicester during 1987 we found a reduction in the number of transplants (table) consequent on a diminishing supply of donor organs despite vigorous campaigns to encourage organ donation. No transplantations from living donors had been performed in the area since 1984 even though seven of the eight previous recipients had functioning grafts. Possible reasons for the decline in transplantations from living donors were the excellent survival of patients with grafts from cadavers after treatment with cyclosporin, uncertainty over the long Number of patients receiving organ transplants in Leicester, 1975-87 From From  cadavers living donors   1975  5  1976  6  1977  13  1978  17  1  1979  10  1980  17  1981  14  198)   28  1  1983  41  1  1984   43  5  1985  38  1986  5 1  1987  38 term effects ofnephrectomy in donors, and the expectation that most patients would get a kidney from a cadaver soon after starting dialysis. Analysis of survival of grafts was complicated by the fact that the date of failure had not always been accurately recorded. The construction of survival curves based on such data has been discussed by Peto.6 Our method was similar to that advocated by Peto but reduced computation time by grouping the time scale. As most centres did not separate technical failures from those due to rejection all failures were grouped together. Grafts that were functioning when patients died were regarded as lost to follow up.
Results
Of The relative age difference between donor and recipient may be important in future planning. Few centres were prepared to transplant a child's kidney to an adult, and most sibling donors had an age difference of no more than 10 years from their recipient. Centres may favour different matching and treatment regimens, such as donor specific transfusion.'" An awareness of these differences among centres has been of benefit in transplantation from cadavers, and information should clearly be shared if transplantation from living donors is to expand more widely. 112
If living donor transplantation is to be more widely accepted then both doctors and patients need to be familiar with its potential benefits and hazards. The advantages may be seen as excellent survival of grafts, short waiting time, and a cost saving to the NHS. Despite the advances in immunosuppressive treatment over the past 20 years the survival of transplants from cadavers with cyclosporin treatment is only now approaching the one year survival of 80-90% obtained with transplants from living donors. '3 The excellent long term results of living donor transplantation shown in this study (60% survival at 20 years) is in contrast to the poor long term results predicted for transplants from cadavers in patients treated with azathioprine and cyclosporin.'4 National statistics show that many patients wait more than two years for a reasonably matched kidney from a cadaver. 4 Prolonged dialysis is expensive both financially and in terms of hardship to the family.'5 16 A successful transplant saves the NHS £30 000,'7 and on average it costs less than £500 for routine investigations (for example, intravenous urography, renal arteriography) of a potential donor. '8 The disadvantages of living donor transplantation have been well established in American series and relate mainly to the risk ofmortality or morbidity in the donor. [19] [20] [21] Though one in 1600 donors die after nephrectomy,' this risk has been estimated to be less than that of dying from a road traffic accident. Postoperative morbidity has been estimated to be 1-2%, the main problems being deep venous thrombosis, pulmonary embolism, and wound infection." 1820 The longer term consequences of donating a kidney have been investigated intensively over the past few years.22-25 Recent reviews of 25 years of follow up found no significant risk to the donor in surviving with a single kidney provided that recognised criteria for selection had been used.52425 Though proteinuria has been found in one third ofdonors, it is non-progressive and believed to be related to hereditary factors.5 Only two of almost 10000 living donors have been reported to have developed end stage renal failure. 24 An expansion of living donor transplantation could take place in two stages. Firstly, relatives could, depending on their cultural and religious views, be routinely screened as possible donors. Secondly, family members other than blood relatives could be considered as a source of kidneys. The prospect of using an unrelated living donor has been widely discussed in recent years, but the debate that rightly outlawed payment for transplantation cast a shadow over the ethics of expanding living donor transplant programmes.2627
The spouse most commonly carries the burden of the ailing patient and has most to gain from the wellbeing that a successful transplant restores. Recent studies suggest that spouse to spouse kidney transplantation with combined immunosuppressive treatment can result in excellent graft function. 28 
Introduction
Thrombosis is a common feature of both unstable angina and death from ischaemic heart disease and unstable angina. This may be related to enhanced platelet activity' 2 or increased amounts of fibrinogen and factor VII, which have been associated with fatal and non-fatal ischaemic heart disease.36 The effect that aspirin has on the function of platelets has been shown to reduce morbidity and mortality in patients with unstable angina and myocardial infarction and to be probably beneficial in the primary and secondary prevention of myocardial infarction.7-20 Trials have tended to use progressively lower doses of aspirin as these cause maximum inhibition of synthesis of thromboxane by platelets, have a minimal effect on synthesis of prostacyclin by vessel walls, and substantially prolong the bleeding time.2"23 For these reasons doses ofaspirin of less than 100 mg a day might theoretically be more effective than higher doses, but for the same reasons they might render patients prone to bleeding that is also seen with higher doses.7"20 Anticoagulant treatment with warfarin has also been used to prevent myocardial reinfarction. Although it is probably beneficial,24 its continued use causes a progressive increase in bleeding. 25 An alternative approach is to use lower doses to normalise the increased activity of factor VII found in patients prone to vascular disease,6 but whether this would cause less bleeding is as yet unproved.
Possibly optimum benefit would accrue from combining low doses of aspirin and warfarin, and this approach is to be investigated by the Medical Research Council in a large community based study.26 Because a combination of treatments has the potential to enhance harm (particularly gastrointestinal bleeding) as much as benefit we investigated the effect of low doses of aspirin and warfarin, alone and in combination, on gastric mucosal bleeding.
Subjects and methods
Twenty healthy non-smoking male volunteers aged 19 to 22 participated in the study. They did not have a BMJ VOLUME 298 25 FEBRUARY 1989 
